Element Biosciences

Element Biosciences is a private, commercial-stage company that has established itself as a disruptive player in the next-generation sequencing (NGS) and multiomics market. Its core technology, the AVITI benchtop sequencer and the newer high-throughput VITARI platform, leverages proprietary Avidite Base Chemistry (ABC) to deliver accurate data with simplified workflows, including a novel Direct In Sample Sequencing (DISS) capability. The company is expanding into spatial biology and single-cell analysis with its AVITI24 system, positioning itself as an integrated platform provider. Backed by industry veteran leadership and notable customer testimonials from prestigious institutions, Element is focused on making advanced multiomic tools accessible to a broader range of research labs.

Proprietary Avidite Base Chemistry (ABC) for sequencing, integrated into benchtop (AVITI) and high-throughput (VITARI) sequencing platforms. The AVITI24 system combines this with spatial and single-cell multiomics capabilities, featuring Direct In Sample Sequencing (DISS) to enable library-prep-free workflows.

Element competes directly with Illumina, the dominant market leader in NGS, and other sequencing players like Pacific Biosciences and Oxford Nanopore. In spatial and single-cell multiomics, it competes with specialized leaders like 10x Genomics, NanoString (or its successors), and Vizgen. Its strategy is to differentiate through integrated workflows, superior data quality via ABC chemistry, and cost-effectiveness.